




Supplemental Figure 1. Schematic representation of the synthesis of  $^{18}\text{F}$ -BMS986192.



Supplemental Figure 2. <sup>18</sup>F-BMS986192 tracer uptake at baseline and follow up using four uptake parameters:  $SUV_{max}$ ,  $SUV_{mean}$ ,  $SUV_{peak}$ , and a tumor-to-blood ratio (TBR) derived from the tumour  $SUV_{peak}$  and the aortic blood pool  $SUV_{mean}$  (4 patients, 19 lesions).



Supplemental Figure 3A.  $^{18}\text{F}$ -BMS986192 tracer uptake at baseline as tumor-to-blood ratio (TBR) derived from the tumour  $\text{SUV}_{\text{peak}}$  and the aortic blood pool  $\text{SUV}_{\text{mean}}$ . Data shown for all included patients in this study and shows 42 lesions.



Supplemental Figure 3B. The diameter change during ICI therapy compared to baseline of tumor lesions per patient. Data shown for all included patients in this study and shows 32 lesions. Patient 2 only had lesions that were smaller than 1 cm at baseline and, therefore, had no response evaluable lesions.